Recent news on Interferon Gamma-1B

InterMune Announces First Quarter 2007 Financial Results and ...  -  May 3, 2007
PR Newswire (press release),In March of 2007, InterMune discontinued the Phase 3 INSPIRE trial evaluating Actimmune(R) (interferon gamma-1b) in patients with IPF.

InterMune Discontinues Phase 3 INSPIRE Trial of Actimmune in ...  -  Apr 6, 2007
Drug Newswire (press release),Inc. (NASDAQ:ITMN) today announced that it has discontinued the Phase 3 INSPIRE clinical trial evaluating Actimmune(R) (interferon gamma-1b) in patients

InterMune cuts costs: workforce slashed 50%  -  Mar 23, 2007
Therapeutics Daily (subscription) (press release),...to reduce operating expenses in light of the termination of the INSPIRE trial of Actimunne [interferon gamma 1b] in idiopathic pulmonary fibrosis."

InterMune Reducing Roster By Half To Finance Pipeline  -  Mar 20, 2007
BioWorld Online,The company decided to stop its Phase III trial called INSPIRE with Actimmune (interferon gamma-1b) against idiopathic pulmonary fibrosis after an

Early Termination for Actimmune Study  -  Mar 13, 2007
Facts and Comparisons,InterMune reports the early termination of the INSPIRE study (Actimmune [interferon gamma-1b]) for treating idiopathic pulmonary fibrosis (IPF).

InterMune Discontinues Phase 3 INSPIRE Trial of Actimmune in ...  -  Mar 6, 2007
PharmaLive.com (press release),Inc. today announced that it has discontinued the Phase 3 INSPIRE clinical trial evaluating Actimmune(R) (interferon gamma-1b) in patients with

InterMune Discontinues Phase 3 INSPIRE Trial Of Actimmune In ...  -  Mar 6, 2007
Medical News Today (press release),InterMune, Inc. (Nasdaq: ITMN) today announced that it has discontinued the Phase 3 INSPIRE clinical trial evaluating Actimmune(R) (interferon gamma-1b) in

InterMune stops Ph III Actimune IPF study  -  Mar 6, 2007
Therapeutics Daily (subscription) (press release),California, USA-based drugmaker InterMune says that it has stopped a Phase III trial of its drug Actimunne (interferon gamma 1b) after it failed to meet

InterMune to Extend Filing Date for Annual Report on Form 10-K  -  Mar 16, 2007
PharmaLive.com (press release),2007, to discontinue its Phase 3 INSPIRE trial of Actimmune(R) (interferon gamma-1b) for the potential treatment of patients with idiopathic pulmonary

Intermune stock battered after IPF trial is halted  -  Mar 7, 2007
Pharma Times (subscription),A Phase III clinical trial, called Inspire, which was evaluating Actimmune (interferon gamma-1b) in patients with IPF, a disease of inflammation that

Market Report -- In Play (ITMN)  -  Mar 5, 2007
MSN MoneyPhase 3 INSPIRE clinical trial evaluating Actimmune (interferon gamma-1b) in patients with idiopathic pulmonary fibrosis based upon the recommendation

InterMune (ITMN) Shares Fall After Announcement to Discontinue ...  -  Mar 5, 2007
StreetInsider.com (subscription),InterMune, Inc. (Nasdaq: ITMN) has discontinued the Phase 3 INSPIRE clinical trial evaluating Actimmune (interferon gamma-1b) in patients with idiopathic

InterMune to Present at the SIGnificant Investment Options in ...  -  Feb 23, 2007
PR Newswire (press release),The INSPIRE trial is evaluating Actimmune(R) (interferon gamma-1b) and the CAPACITY program is evaluating pirfenidone. The hepatology portfolio includes the

InterMune Announces Fourth Quarter and Full Year 2006 Financial ...  -  Feb 9, 2007
PharmaLive.com (press release),Total product revenue for the fourth quarter of 2006 was $19.4 million, comprised solely of Actimmune(R) (interferon gamma-1b) revenue, compared to $29.0

US Attorney Kevin V. Ryan Announces Departure - Northern District ...  -  Feb 15, 2007
Lawfuel (press release),...criminal charges and civil liability in connection with its illegal promotion and marketing of its drug Actimmune (Interferon gamma-1b) in October 2006.

InterMune Achieves Manufacturing Milestone in HCV Collaboration ...  -  Jan 9, 2007
PharmaLive.com (press release),The INSPIRE trial is evaluating Actimmune(R) (interferon gamma-1b) and the CAPACITY program is evaluating pirfenidone. The hepatology portfolio includes the

InterMune Initiates Phase 1a Clinical Trial Evaluating Hepatitis C ...  -  Dec 20, 2006
Drug Newswire (press release),The INSPIRE trial is evaluating Actimmune(R) (interferon gamma-1b) and the CAPACITY program is evaluating pirfenidone. The hepatology portfolio includes the

United States: Intermune’s CIA Signals OIG’s Expectations For ...  -  Dec 5, 2006
Mondaq News Alerts (subcription),...$37 million to resolve criminal charges and civil liability in connection with the promotion and marketing of its drug Actimmune (Interferon gamma-1b).

InterMune to Present at the ThinkEquity Partners ThinkTank  Nov 8, 2006
...with IPF. The INSPIRE trial is evaluating Actimmune® (interferon gamma-1b) and the CAPACITY program is evaluating pirfenidone. The ... -Yahoo! News (press release) InterMune Announces Third Quarter Financial Results and Business ...  Oct 26, 2006
...that it had finalized its comprehensive settlement with the government concerning promotional activities for Actimmune® (interferon gamma-1b) by former ... -Yahoo! News (press release) InterMune Presents Preclinical Data Showing Additive Anti-Fibrotic ...  Oct 24, 2006
...study results involving its two Phase III drug candidates for idiopathic pulmonary fibrosis (IPF), Actimmune(R) (interferon gamma-1b) and pirfenidone, at CHEST ... -PR Newswire (press release), InterMune to pay $37M to settle federal charges  Oct 26, 2006
The Brisbane-based biopharmaceutical company was facing criminal and civil charges in connection with the drug Actimmune7 (Interferon gamma-1b), Ryan said. ... -San Jose Business Journal, US Law - Biopharmaceutical Company Intermune Inc To Pay Nearly $37 ...  Oct 26, 2006
...$37 million to resolve criminal charges and civil liability in connection with its illegal promotion and marketing of its drug Actimmune7 (Interferon gamma-1b ... -Lawfuel (press release), Stiefel Plans $640M Acquisition Of Dermatology Firm Connetics  Oct 23, 2006
The firm has a historical link with strong-selling Actimmune (interferon gamma-1b), approved for chronic granulomatous disease and severe, malignant ... -BioWorld Online, InterMune to Present Research on ITMN-191 in Hepatitis C at Two ...  Oct 24, 2006
Presentation (#1134): Final Results of pilot study evaluating safety, viral clearance and antifibrotic efficay of treatment with Interferon Gamma-1b plus an ... -PR Newswire (press release), Interferon-Gamma-1b May Improve Survival of Moderate IPF  Aug 31, 2006
...idiopathic pulmonary fibrosis (IPF) may survive slightly longer and experience a better quality of life when treated with interferon-gamma-1b instead of ... -Medscape (subscription)

InterMune Elects Lars Ekman, MD, Ph.D. to Board of Directors  Sep 21, 2006
...with IPF. The INSPIRE trial is evaluating Actimmune® (interferon gamma-1b) and the CAPACITY program is evaluating pirfenidone. The ... -Yahoo! News

Biogen Idec Licenses PAH Drug From MondoBiotech  Sep 14, 2006
The company also has out-licensed rights to interferon gamma-1b to InterMune Inc., of Brisbane, Calif., for idiopathic pulmonary fibrosis and asthma. ... -BioWorld Online

InterMune to Present at the Bear Stearns Healthcare Conference and ...  Sep 6, 2006
...evaluating possible therapeutic candidates for treatment of patients with IPF: the INSPIRE trial is evaluating Actimmune(R) (interferon gamma-1b) and the ... -PharmaLive.com

United States: Intermune’s CIA Signals OIG’s Expectations For ...  -  Dec 5, 2006
Mondaq News Alerts (subcription),...$37 million to resolve criminal charges and civil liability in connection with the promotion and marketing of its drug Actimmune (Interferon gamma-1b).

InterMune to Present at the BMO Capital Markets Focus on ...  -  Nov 30, 2006
PharmaLive.com (press release),The INSPIRE trial is evaluating Actimmune(R) (interferon gamma-1b) and the CAPACITY program is evaluating pirfenidone. The hepatology portfolio includes

InterMune Announces Second Quarter Financial Results  Jul 28, 2006
...in connection with a proposed comprehensive settlement with the government concerning promotional activities for Actimmune(R) (interferon gamma-1b) by former ... -Drug Newswire

InterMune Appoints John C. Hodgman as Chief Financial Officer  Jul 31, 2006
...evaluating possible therapeutic candidates for treatment of patients with IPF: the INSPIRE trial is evaluating Actimmune(R) (interferon gamma-1b) and the ... -PR Newswire

InterMune to Release Second Quarter 2006 Financial Results on July ...  Jul 10, 2006
...evaluating possible therapeutic candidates for treatment of patients with IPF: the INSPIRE trial is evaluating Actimmune® (interferon gamma-1b) and the ... -Yahoo! News



InterMune Completes Enrollment of the Phase III INSPIRE Trial  Apr 18, 2006
...the completion on April 13 of patient enrollment in the INSPIRE trial, a pivotal Phase III clinical trial of Actimmune(R) (interferon gamma-1b) in patients ... - International News Service

InterMune Initiates Phase III Program Evaluating Pirfenidone in ...  Apr 27, 2006
The pulmonology pipeline includes the two most clinically advanced development programs in the field of IPF: Actimmune® (interferon gamma-1b) is being ... - Yahoo! News

InterMune Announces First Quarter Financial Results and Business ...  Apr 27, 2006
Total revenue for the first quarter of 2006 was $24.4 million, comprised solely of Actimmune® (interferon gamma-1b) sales compared to first quarter 2005 total ... - Yahoo! News

InterMune to Present at the Deutsche Bank 2006 Health Care ...  Apr 26, 2006
The pulmonology portfolio includes Actimmune® (interferon gamma-1b), which is being evaluated in the INSPIRE Trial, a Phase III study in patients with IPF ... - Yahoo! News





InterMune to Release First Quarter 2006 Financial Results on April ...  Apr 6, 2006
The pulmonology portfolio includes Actimmune® (interferon gamma-1b), which is being evaluated in the INSPIRE Trial, a Phase III study in patients with IPF ... - Yahoo! News



InterMune to Present at the 5th Annual JMP Securities Research ...  Mar 2, 2006
The pulmonology portfolio includes Actimmune(R) (interferon gamma-1b), which is being evaluated in the INSPIRE Trial, a Phase III study in patients with IPF ... - PR Newswire,

InterMune Announces Fourth Quarter and Year End 2005 Financial ...  Feb 2, 2006
Total revenue for the fourth quarter of 2005, which included revenue from Actimmune(R) (interferon gamma-1b) and Other Products (Aralast(R)), was $28.7 million ... - PR Newswire,

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional